{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:15:36Z","timestamp":1763705736793,"version":"3.44.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bulcan.2019.09.011","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T22:45:28Z","timestamp":1576709128000},"page":"244-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Radioth\u00e9rapie st\u00e9r\u00e9otaxique\u00a0: changement de monde ou effet de mode\u00a0?"],"prefix":"10.1016","volume":"107","author":[{"given":"Alexis","family":"Vallard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Vial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Jmour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amel","family":"Rehailia-Blanchard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane-Chlo\u00e9","family":"Trone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Sotton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6101-1016","authenticated-orcid":false,"given":"Elisabeth","family":"Daguenet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Guy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Magn\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2019.09.011_bib0330","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/COC.0b013e31826e053d","article-title":"American College of Radiology (ACR) and American Society for Radiation Oncology (ASTRO) practice guideline for the performance of Stereotactic Radiosurgery (SRS)","volume":"36","author":"Seung","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0335","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.meddos.2008.06.002","article-title":"Effect of MLC leaf width and PTV margin on the treatment planning of intensity-modulated stereotactic radiosurgery (IMSRS) or radiotherapy (IMSRT)","volume":"34","author":"Chang","year":"2009","journal-title":"Med Dosim"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0340","doi-asserted-by":"crossref","first-page":"218","DOI":"10.14316\/pmp.2014.25.4.218","article-title":"Dosimetric verifications of the output factors in the small field less than 3cm2\u00a0using the gafchromic EBT2\u00a0films and the various detectors","volume":"25","author":"Oh","year":"2014","journal-title":"Prog Med Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0345","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.ijrobp.2019.08.007","article-title":"A prospective single-arm phase II study of stereotactic magnetic-resonance-guided adaptive radiotherapy for prostate cancer: early toxicity results","volume":"105","author":"Bruynzeel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0350","unstructured":"J. Kang, MRI-guided Stereotactic Body Radiotherapy (SBRT) with simultaneous integrated boost for prostate cancer - Full Text View - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03664193.(accessed September 20, 2019)."},{"key":"10.1016\/j.bulcan.2019.09.011_bib0650","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","article-title":"ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Postmus","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0360","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2009.12.008","article-title":"Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications","volume":"94","author":"Chi","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0655","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0375","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1\u00a0non-small-cell lung cancer (TROG 09.02\u00a0CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0380","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.breast.2015.12.002","article-title":"Stereotactic body radiation therapy: A promising chance for oligometastatic breast cancer","volume":"26","author":"Scorsetti","year":"2016","journal-title":"Breast"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0385","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/01.brs.0000251863.76595.a2","article-title":"Radiosurgery for spinal metastases: clinical experience in 500\u00a0cases from a single institution","volume":"32","author":"Gerszten","year":"2007","journal-title":"Spine"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0390","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.radonc.2006.08.024","article-title":"Phase II trial of hypofractionated stereotactic radiotherapy for brain metastases: results and toxicity","volume":"81","author":"Ernst-Stecken","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0395","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cncr.24082","article-title":"Hypofractionated stereotactic radiotherapy for the treatment of brain metastases","volume":"115","author":"Kwon","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/COC.0b013e31828aadac","article-title":"Fractionated stereotactic radiosurgery for large brain metastases","volume":"38","author":"Wegner","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0660","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11060-008-9700-8","article-title":"Hypofractionated stereotactic radiotherapy in combination with whole brain radiotherapy for brain metastases","volume":"91","author":"Giubilei","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0665","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijrobp.2010.05.033","article-title":"Single-dose versus fractionated stereotactic radiotherapy for brain metastases","volume":"81","author":"Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0415","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11060-015-1881-3","article-title":"Long-term risk of radionecrosis and imaging changes after stereotactic radiosurgery for brain metastases","volume":"125","author":"Kohutek","year":"2015","journal-title":"J Neurooncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0420","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.ctrv.2011.04.004","article-title":"Stereotactic radiosurgery and hypofractionated stereotactic radiotherapy: normal tissue dose constraints of the central nervous system","volume":"37","author":"Milano","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0425","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(04)16250-8","article-title":"Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508\u00a0randomised trial","volume":"363","author":"Andrews","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0430","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0435","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952\u201326001\u00a0study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0440","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1\u00a0to 3\u00a0brain metastases: a randomized clinical trial","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0445","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0360-3016(99)00198-4","article-title":"Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases","volume":"45","author":"Kondziolka","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0450","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.canrad.2016.07.041","article-title":"Radioth\u00e9rapie des m\u00e9tastases c\u00e9r\u00e9brales","volume":"20","author":"Latorzeff","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0455","first-page":"108","article-title":"Radiotherapy for hepatocellular carcinoma: new indications and directions for future study","author":"Ohri","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0460","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1002\/cncr.27533","article-title":"Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization","volume":"118","author":"Kang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0465","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.radonc.2015.04.006","article-title":"Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma","volume":"115","author":"Huertas","year":"2015","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0670","doi-asserted-by":"crossref","first-page":"e77472","DOI":"10.1371\/journal.pone.0077472","article-title":"Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity","volume":"8","author":"Bibault","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0475","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.canrad.2015.05.020","article-title":"Follow-up after stereotactic body radiation therapy for liver tumours: a review of the literature and recommendations","volume":"19","author":"Janoray","year":"2015","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0480","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1200\/JCO.2008.19.6329","article-title":"Multi-institutional phase I\/II trial of stereotactic body radiation therapy for liver metastases","volume":"27","author":"Rusthoven","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0485","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ijrobp.2015.11.026","article-title":"Lymphocyte-sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer","volume":"94","author":"Wild","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0675","series-title":"Th\u00e9saurus National de Canc\u00e9rologie Digestive","article-title":"Cancer du pancreas","author":"Neuzillet","year":"2018"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0495","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2009.08.046","article-title":"Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer","volume":"78","author":"Mahadevan","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0500","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","author":"Chuong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0505","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/1748-717X-8-254","article-title":"Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer","volume":"8","author":"Rajagopalan","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0510","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COC.0b013e3181d270b4","article-title":"Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas","volume":"34","author":"Rwigema J-CM","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0515","doi-asserted-by":"crossref","first-page":"479","DOI":"10.21037\/jgo.2015.10.01","article-title":"Stereotactic body radiotherapy for the pancreas: a critical review for the medical oncologist","volume":"7","author":"Kim","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0520","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1002\/cncr.30856","article-title":"Stereotactic body radiotherapy for unresected pancreatic cancer: a nationwide review","volume":"123","author":"de Geus","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0525","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s13014-015-0489-2","article-title":"Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas","volume":"10","author":"Elhammali","year":"2015","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0530","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.canrad.2016.07.032","article-title":"Delineation of organs at risk and dose constraints","volume":"20Suppl","author":"No\u00ebl","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0535","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2018.06.105","article-title":"Stereotactic ablative radiation therapy for the comprehensive treatment of oligometastatic tumors (SABR-COMET): results of a randomized trial","volume":"102","author":"Palma","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0540","unstructured":"2018\u00a0ASTRO: Overall Survival With Local Consolidative Therapy in Oligometastatic NSCLC - The ASCO Post n.d. http:\/\/www.ascopost.com\/News\/59408 (accessed February 20, 2019)"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0545","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2\u00a0randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0550","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0555","unstructured":"Trial reports randomized evidence high-dose radiation is effective for men whose prostate cancer has spread - American Society for Radiation Oncology (ASTRO) - American Society for Radiation Oncology (ASTRO). ASTRO n.d. https:\/\/www.astro.org\/News-and-Publications\/News-and-Media-Center\/News-Releases\/2019\/Trial-reports-randomized-evidence-high-dose-radiat.(accessed September 20, 2019)."},{"key":"10.1016\/j.bulcan.2019.09.011_bib0560","first-page":"109","article-title":"Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial","author":"Ruers","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0565","unstructured":"Radiosurgery Compared To External Beam Radiotherapy for Localized Spine Metastasis: Phase III Results of NRG Oncology\/RTOG 0631 - International Journal of Radiation Oncology \u2022 Biology \u2022 Physics n.d. https:\/\/www.redjournal.org\/article\/S0360-3016(19)31217-9\/fulltext (accessed September 20, 2019)."},{"key":"10.1016\/j.bulcan.2019.09.011_bib0570","unstructured":"Search of: SBRT | Recruiting Studies | Interventional Studies - List Results - ClinicalTrials.gov n.d. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=SBRT&type=Intr&rslt=&recrs=a&age_v=&gndr=&intr=&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&lupd_s=&lupd_e=&sort= (accessed September 20, 2019)"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0575","unstructured":"ESTRO - ESTRO News n.d. https:\/\/www.estro.org\/About\/News\/EORTC-and-ESTRO-announce-E2-RADIatE-platform%E2\u00a0%80\u00a0%99s-fir (accessed September 20, 2019)"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0580","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ijrobp.2017.12.014","article-title":"Comparison of stereotactic body radiation therapy and radiofrequency ablation in the treatment of intrahepatic metastases","volume":"100","author":"Jackson","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0585","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.ijrobp.2016.04.016","article-title":"Comparison of the effectiveness of radiofrequency ablation with stereotactic body radiation therapy in inoperable stage I non-small cell lung cancer: a systemic review and pooled analysis","volume":"95","author":"Bi","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0590","doi-asserted-by":"crossref","first-page":"450","DOI":"10.6004\/jnccn.2018.7269","article-title":"Stereotactic body radiation therapy versus nonradiotherapeutic ablative procedures (laser\/cryoablation and electrocautery) for early-stage non-small cell lung cancer","volume":"17","author":"Baine","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0595","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1148\/radiol.2018180979","article-title":"Survival rates after thermal ablation versus stereotactic radiation therapy for stage 1\u00a0non-small cell lung cancer: a national cancer database study","volume":"289","author":"Uhlig","year":"2018","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0600","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/theoncologist.2015-0085err","article-title":"The metastatic spine disease multidisciplinary working group algorithms","volume":"24","author":"Wallace","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0605","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1016\/S1470-2045(17)30612-5","article-title":"An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report","volume":"18","author":"Spratt","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0610","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1148\/93.2.410","article-title":"The abscopal effect in malignant lymphoma and its relationship to lymphocyte circulation","volume":"93","author":"Nobler","year":"1969","journal-title":"Radiology"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0615","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0620","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0625","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMc1203984","article-title":"Abscopal effect in a patient with melanoma","volume":"366","author":"Hiniker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0630","doi-asserted-by":"crossref","first-page":"e1046028","DOI":"10.1080\/2162402X.2015.1046028","article-title":"A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab","volume":"4","author":"Chandra","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0635","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0640","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40425-016-0156-7","article-title":"Current clinical trials testing the combination of immunotherapy with radiotherapy","volume":"4","author":"Kang","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0645","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","article-title":"The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant","volume":"41","author":"Reynders","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.bulcan.2019.09.011_bib0325","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2016.03.067","article-title":"Can immunostimulatory agents enhance the abscopal effect of radiotherapy?","volume":"62","author":"Levy","year":"2016","journal-title":"Eur J Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119304072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119304072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:32:54Z","timestamp":1757791974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455119304072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0007455119304072"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.09.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radioth\u00e9rapie st\u00e9r\u00e9otaxique\u00a0: changement de monde ou effet de mode\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}